|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 基于自适应变异概率二进制PSO的球磨制粉系统控制(英文)显示文摘研究了一种新型自适应变异概率二进制粒子群算法。提出的自适应变异策略通过以一定的概率进行动态比特转换帮助算法更好地保持种群多样性和搜索新解,从而有效防止算法早熟。最终将提出的自适应变异概率二进制粒子群算法(adaptive mutation based pobability binary PSO,APBPSO)用于球磨制粉系统这一复杂多变量对象的PID控制器优化设计中以验证算法性能。多变量控制器分别采用了三种多目标优化目标函数,仿真结果表明提出APBPSO能有效避免陷入局部最优,其对控制器优化性能优于粒子群优化算法、离散二进制粒子群优化算法及基本的概率二进制粒子群优化算法。 | Muhammad Ilyas MENHAS 费敏锐 王灵 钱麟 | 2011 | 系统仿真学报2011，23，8： | 11 |
| 2 | A novel modified binary differential evolution algorithm and its applications显示文摘 | Ling Wang Xiping Fu Yunfei Mao Muhammad Ilyas Menhas Minrui Fei | 2012 | Neurocomputing2012，，： | 1 |
| 3 | Coordinated Controller Tuning of a Boiler Turbine Unit with New Binary Particle Swarm Optimization Algorithm显示文摘Coordinated controller tuning of the boiler turbine unit is a challenging task due to the nonlinear and coupling characteristics of the system.In this paper,a new variant of binary particle swarm optimization (PSO) algorithm,called probability based binary PSO (PBPSO),is presented to tune the parameters of a coordinated controller.The simulation results show that PBPSO can effectively optimize the control parameters and achieves better control performance than those based on standard discrete binary PSO,modified binary PSO,and standard continuous PSO. | Muhammad Ilyas Menhas Ling Wang Min-Rui Fei Cheng-Xi Ma | 2011 | International Journal of Automation and computing2011，8，2： | 1 |
| 4 | Clinical implications of adiponectin and inflammatory biomarkers in type 2 diabe-tes mellitus显示文摘 | Menha S Magda SM Adel AFA | 2009 | Dis Markers2009，27，6： | 1 |
| 5 | Comparative performance analysis of various binary coded PSO algorithms in multivariable PID controller design显示文摘 | MENHAS M I WANG L FEI M R | 2012 | Expert Systems with Applications2012，，39： | 1 |
| 6 | Training feedforward networks with the Marquardt algorithm显示文摘 | Hagan M T Menha J M B | 1994 | IEEE Transactions on Neural Networks1994，5，6： | 1 |
| 7 | Comparative performance analysis of various binary coded PSO algorithms in multi variable PID controller design显示文摘 | MENHAS M I WANG L FEI M | 2012 | Expert Systems with Applications2012，39，： | 1 |
| 8 | Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer显示文摘 | Sanaa Eissa Samir F. Zohny Menha Swellam Manar H. Mahmoud Tarek Mostafa El-Zayat Ahmed M. Salem | 2008 | Clinical Biochemistry2008，，16： | 1 |
| 9 | Real/bi-nary coo-perative and coevolving swarms based-multivariable PID controller design of ball mill pulverizing system显示文摘 | Menhas M I Fei M R Wang L | 2010 | Energy Conversion and Management2010，54，1： | 1 |
| 10 | 未化疗的广泛期小细胞肺癌患者吉西他滨联合顺铂诱导化疗后口服依托泊苷维持治疗疗效评估(英文)显示文摘Objective:The aim of our study was to evaluate the response and tolerability to treatment when using gemcitabine-cisplatin combination(GC),followed by maintenance therapy of oral etoposide for non-progressive patients in trial to improve progression free survival and overall survival.Methods:Thirty nine patients with extensive small cell lung cancer(SCLC) and ECOG ≤ 2 received 4 cycles of chemotherapy consisting of gemcitabine 1000 mg/m2(day 1 and 8) cisplating 75 mg/m2(day 1) every three weeks.Twenty seven non-progressive patients after 4 cycles of chemotherapy were randomized either to receive oral etoposide 50 mg/m2 for consecutive 15 days every 3 weeks vs no therapy for three months or progression.Results:Thirty nine eligible patients treated with GC,27 non progressive patients were subsequently randomized to oral etoposide or observation.Median follow-up was 18 months.The overall response rate to GC was 59% and toxicity to oral etoposide was mild.There was improvement in median progression-free survival(PFS) favoring the maintenance arm of 10.5 months vs 7 months(P < 0.05).Median overall survival(OS) had improved towards the maintenance arm(13 vs 11.5 months).One year survival(60% vs 24%),18 months survival(20% vs 5%) favoring the maintenance.Multivariate analysis revealed that age,performance status,maintenance therapy,and response to treatment were independent prognostic factors for OS.Age,maintenance therapy,and response to treatment were highly significant factors for PFS.Conclusion:Gemcitabine-cisplatin is an effective and tolerable regiment for extensive disease of SCLC.The addition of 3 months of oral etoposide in non progressing patients was associated with a significant improvement of PFS and longer OS. | Lobna R Ezz Elarab Manal M Abdel Wahab Menha Swellam Zakaria Mostafa | 2010 | The Chinese-German Journal of Clinical Oncology2010，9，10： | 0 |
| 11 | 绝经后妇女患早期乳腺癌后阿那曲唑及他莫昔芬治疗所致的有关骨矿物质密度和骨生物标记物Osteocalcin的骨骼事件比较(英文)显示文摘Objective:Postmenopausal women with breast cancer are at increased risk of bone loss because of age related estrogen deficiency face which accelerated with the use of aromatase inhibitors(AIs).We aimed to study the effect on bone mineral density(BMD) and bone formation biomarker osteocalcin level in postmenopausal breast cancer patients,for the first three years of adjuvant hormonal treatment of both groups Tamoxifen versus Anastrozol.Methods:One-hundered postmenopausal breast cancers were prospectively randomized to receive either Tamoxifen 20 mg/day(n = 50) or Anastrozole 10 mg(n = 50).Both BMD and osteocalcin were assessed initially before treatment and then at regular intervals for both groups.Results:Use of Tamoxifen was associated with significant annual decrease in osteocalcin(P = 0.001),whereas Anastrozole group had gradual increase of the annual levels(P < 0.01).BMD decreased significantly in Anastrozole versus Tamoxifen groups(2.6% vs.0.4%,P < 0.001).Osteoporosis T <-2.5 was reported significantly higher in Anastrozole group(P < 0.01).Women with initial osteopenia in Anastrozole group showed significant decrease in BMD(P < 0.05).The addition of bisphosphonate for patients with early osteoporosis markedly improved both osteocalcin level and BMD.Conclusion:Tamoxifen preserves BMD in postmenopausal breast cancer patients,whereas Anastrozole accelerates age associated fall in BMD especially in the first year of therapy,moreover,the addition of bisphosphonate can help to decrease the skeletal related events associated with treatment to ensure better quality of life with treatment. | Lobna R Ezz Elarab Menha Swellam Manal M Abdel Wahab Karima M Maher | 2010 | The Chinese-German Journal of Clinical Oncology2010，9，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员